Post by
lonc17 on May 28, 2023 8:53pm
IND213
These results from Bracelet (yet to be updated to May but almost certain to be strong) go a very long way toward validating IND213.
The results from IND213 were very impressive but always in doubt due to an unfortunate fluke. There was a built in bias in the data due to the test group having favourable CELTIL scores vs the control goup. I bielieve the Ecog scores were also skewed in favour of the test goup.
This was IMO the reason why ONC failed to secure partner or buyout and an immediate launch into P3.
But now we have Bracelet. Having two randomized trials showing statistical signifance in favour of Pelareorep is very impressive and gives a fresh look at IND213.
Now when ONC says, "a near doubling of OS" it is much more convincing that this is due to treatment affect rather than a lucky roll of the dice (during randomization).
I say again that for those close to this story this week may be the best buying opporutnity in the past 20 years.
Comment by
westcoast1000 on May 28, 2023 10:09pm
Ionc, Thanks for these insightful comments. I did not recall there was a flukey difference in CELTIL and ecog scores on the previous round. Your comments are very helpful. I wish I were not in so deep already in terms of this buying opportunity. I have been pursuing buying opportunities at inopportune times for many years.
Comment by
lonc17 on May 29, 2023 12:30am
Slight correction. I said CELTIL when I meant CTC (Cirucluating Tumour Cells)